Oasmia Pharmaceutical Ab Stock Net Income
| OASMY Stock | USD 0.0001 0.00 0.00% |
As of the 13th of February 2026, Oasmia Pharmaceutical holds the Coefficient Of Variation of (659.95), variance of 198.56, and Risk Adjusted Performance of (0.11). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oasmia Pharmaceutical, as well as the relationship between them.
Oasmia Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oasmia Pharmaceutical's valuation are provided below:Oasmia Pharmaceutical AB does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Oasmia |
Oasmia Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oasmia Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oasmia Pharmaceutical.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Oasmia Pharmaceutical on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Oasmia Pharmaceutical AB or generate 0.0% return on investment in Oasmia Pharmaceutical over 90 days. Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Swede... More
Oasmia Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oasmia Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oasmia Pharmaceutical AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 116.67 | |||
| Value At Risk | (16.00) |
Oasmia Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oasmia Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oasmia Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Oasmia Pharmaceutical historical prices to predict the future Oasmia Pharmaceutical's volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.96) | |||
| Total Risk Alpha | (3.37) | |||
| Treynor Ratio | 0.8254 |
Oasmia Pharmaceutical February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | 0.8354 | |||
| Mean Deviation | 5.17 | |||
| Coefficient Of Variation | (659.95) | |||
| Standard Deviation | 14.09 | |||
| Variance | 198.56 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.96) | |||
| Total Risk Alpha | (3.37) | |||
| Treynor Ratio | 0.8254 | |||
| Maximum Drawdown | 116.67 | |||
| Value At Risk | (16.00) | |||
| Skewness | (5.45) | |||
| Kurtosis | 34.77 |
Oasmia Pharmaceutical Backtested Returns
Oasmia Pharmaceutical maintains Sharpe Ratio (i.e., Efficiency) of -0.16, which implies the firm had a -0.16 % return per unit of risk over the last 3 months. Oasmia Pharmaceutical exposes seventeen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oasmia Pharmaceutical's Coefficient Of Variation of (659.95), variance of 198.56, and Risk Adjusted Performance of (0.11) to confirm the risk estimate we provide. The company holds a Beta of -2.6, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oasmia Pharmaceutical are expected to decrease by larger amounts. On the other hand, during market turmoil, Oasmia Pharmaceutical is expected to outperform it. At this point, Oasmia Pharmaceutical has a negative expected return of -2.27%. Please make sure to check Oasmia Pharmaceutical's risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to decide if Oasmia Pharmaceutical performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.37 |
Below average predictability
Oasmia Pharmaceutical AB has below average predictability. Overlapping area represents the amount of predictability between Oasmia Pharmaceutical time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oasmia Pharmaceutical price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Oasmia Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | -0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Oasmia Pharmaceutical AB reported net income of (132.72 Million). This is 138.89% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 123.24% higher than that of the company.
Oasmia Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oasmia Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oasmia Pharmaceutical could also be used in its relative valuation, which is a method of valuing Oasmia Pharmaceutical by comparing valuation metrics of similar companies.Oasmia Pharmaceutical is currently under evaluation in net income category among its peers.
Oasmia Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0875 | |||
| Current Valuation | 6.58 M | |||
| Shares Outstanding | 179.35 M | |||
| Number Of Shares Shorted | 20.72 K | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 31.16 X | |||
| Revenue | 26.19 M | |||
| Gross Profit | (15.25 M) | |||
| EBITDA | (97.54 M) | |||
| Net Income | (132.72 M) | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.80 X | |||
| Cash Flow From Operations | (145.56 M) | |||
| Short Ratio | 0.03 X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 17 | |||
| Beta | 0.0522 | |||
| Market Capitalization | 21.21 M | |||
| Total Asset | 594.31 M | |||
| Annual Yield | 0.12 % | |||
| Net Asset | 594.31 M |
About Oasmia Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oasmia Pharmaceutical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oasmia Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oasmia Pharmaceutical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oasmia Pink Sheet Analysis
When running Oasmia Pharmaceutical's price analysis, check to measure Oasmia Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oasmia Pharmaceutical is operating at the current time. Most of Oasmia Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Oasmia Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oasmia Pharmaceutical's price. Additionally, you may evaluate how the addition of Oasmia Pharmaceutical to your portfolios can decrease your overall portfolio volatility.